Cargando…

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis

Background: Chronic Kidney Disease (CKD) is a global chronic disease with increasing prevalence in recent years, particularly CKD accompanied by Secondary Hyperparathyroidism (SHPT) leads to reduced quality of life, increased mortality, a considerable economic burden for patients and society. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhuolin, Cai, Lele, Wu, Hong, Xu, Xinglu, Fang, Wenqing, He, Xuan, Wang, Xiao, Li, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333861/ https://www.ncbi.nlm.nih.gov/pubmed/34368073 http://dx.doi.org/10.3389/fpubh.2021.712027

Ejemplares similares

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial
por: Liu, Lin, et al.
Publicado: (2020)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison
por: Zawierucha, Jacek, et al.
Publicado: (2019)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism
por: Xiang, Zeli, et al.
Publicado: (2022)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
por: Riccio, Eleonora, et al.
Publicado: (2015)

Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis
por: Dulfer, R. R., et al.
Publicado: (2019)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl
por: Bothou, Christina, et al.
Publicado: (2018)

Parathyroidectomy versus cinacalcet in the treatment of tertiary hyperparathyroidism after kidney transplantation: a retrospective study
por: Jung, Suyun, et al.
Publicado: (2022)

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
por: Ng, Cheng Han, et al.
Publicado: (2020)

Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism
por: Evans, Marie, et al.
Publicado: (2018)

Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
por: Mawad, Habib, et al.
Publicado: (2017)

Evaluating the Price, Availability, and Affordability of Essential Medicines in Primary Healthcare Institutions: A Mixed Longitudinal and Cross-Sectional Study in Jiangsu, China
por: Wang, Xiao, et al.
Publicado: (2022)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series
por: Ohri, Alpana, et al.
Publicado: (2022)

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review
por: Li, Xiaosong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8f5u381f846te2jh3hvt5d09fc